Pravastatin, a 3-hydroxy-3-methyl-glutharyl coenzyme a inhibitor does not show pleiotropic effects in patients with systemic lupus erythematosus

Rheumatology International

Volumn 29, Issue 3, 2009, Pages 353-354

  Kotyla, Przemyslaw J ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PRAVASTATIN; SIMVASTATIN; TUMOR NECROSIS FACTOR;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; DISEASE COURSE; DRUG EFFICACY; ENDOTHELIUM; HUMAN; IMMUNE RESPONSE; LETTER; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; PLEIOTROPY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LUPUS ERYTHEMATOSUS, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SIMVASTATIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 57649166568     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-008-0683-8     Document Type: Letter

References (5)

1. KH Costenbader MH Liang LB Chibnik 2007 A pravastatin dose-escalation study in systemic lupus erythematosus Rheumatol Int 27 1071 1077
2. J Wajed P Ahmad N Durrington IN Bruce 2004 Prevention of cardiovascular disease in systemic lupus erythematosus-proposed guidelines for risk factor management Rheumatology 43 7 12
3. Kotyla P, Sliwinska-Kotyla B (2008) Therapeutic potential of HMG-CoA reductase inhibitors (statins) in systemic lupus erythematosus. In: Stevard TI (ed) Progress in systemic lupus erythematosus research. Nova Science Publishers, New York, pp 227-243
4. PJ Kotyla B Sliwinska-Kotyla EJ Kucharz 2006 TNF alpha as a potential target in the treatment of SLE: a role for the HMG-CoA reductase inhibitor simvastatin J Rheumatol 33 2361
5. GA Ferreira TP Navarro RW Telles LEC Andrade I Sat 2007 Atorvastatin therapy improves endothelial-dependent vasodilatation in patients with systemic lupus erythematosus: an 8 weeks controlled trial Rheumatology 46 1560 1565